Annual report pursuant to Section 13 and 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.23.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Net Revenue $ 75,743 $ 68,791  
Cost of goods - product revenue (30,775) (32,084)  
Research and development (134,876) (128,865)  
Selling, general and administrative (113,656) (86,843)  
Wire transfer fraud loss 0 (9,540)  
Other income (expense) (9,900) 24,188  
Income tax expense (449) (473) $ (500)
Net loss (213,913) (164,826)  
Dermatology Products Sales      
Segment Reporting Information [Line Items]      
Net Revenue 73,669 63,134  
Cost of goods - product revenue (30,775) (32,084)  
Research and development (10,943) (16,558)  
Selling, general and administrative (59,503) (39,895)  
Wire transfer fraud loss   (9,540)  
Other income (expense) (2,048) (7,479)  
Net loss (29,600) (42,422)  
Pharmaceutical and Biotechnology Product Development      
Segment Reporting Information [Line Items]      
Net Revenue 2,074 5,657  
Cost of goods - product revenue 0 0  
Research and development (123,933) (112,307)  
Selling, general and administrative (54,153) (46,948)  
Wire transfer fraud loss   0  
Other income (expense) (7,852) 31,667  
Income tax expense   (473)  
Net loss $ (184,313) $ (122,404)